Simris Alg

Simris evaluating options to expand its ADC-payload development programme and prepare for the next funding round to accelerate its plans.

Simris is evaluating two strategic development paths that both require additional funding: continued focus on pre-clinical development of its Microcystin-based ADC platform, or a more capital-intensive expansion involving the integration of an experienced ADC team and a clinically validated payload class potentially enabling a first-in-human study by 2028 and transforming the company into a fully integrated ADC development platform.

Simis provides an update on the divestment of its assets in Hammenhög, Sweden

Simris Group AB (“Simris” or the “Company”) announces that discussions with Immunrise Biocontrol France SAS (“Immunrise”) continue, on a non-exclusive basis, beyond the deadline of March 1, 2026 and with both parties working towards the completion of the transaction.

SIMRIS GROUP YEAR-END REPORT JANUARY-DECEMBER 2025

Bulletin from Simris Group AB’s extraordinary general meeting

Simris Group AB (publ), reg. no. 556841–9187 (the "Company"), held an extraordinary general meeting on 19 January 2026. Below follows a summary of the resolutions that were passed at the general meeting.

Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Simris Group AB (“Simris” or the “Company”) has entered into a Memorandum of Understanding (“MoU”) with Immunrise Biocontrol France SAS (“Immunrise”) regarding a potential divestment of the Company’s assets related to microalgae production in Hammenhög, Sweden.

Simris Group AB (publ) receives notice of conversion of convertible bonds

On 27 July 2025, the board of directors of Simris Group AB (publ) ("Simris Group" or the "Company") resolved, by virtue of the authorisation granted by the annual general meeting held on 28 May 2025, on a directed issue of convertible debentures, of maximum EUR 678,000 (the “Convertibles”). The issue of the Convertibles was directed to Praesidio Wealth Solutions Fund SPC Ltd, Osiris International Trustees Limited as trustee of the Mountain High Trust, Russel Ziman and Glen Phillip Heneck (the “Investors”).

Notice of extraordinary general meeting in Simris Group AB (publ)

English version follow after the Swedish version.

Simris Group AB resolves on directed issue of units, proposes that an extraordinary general meeting resolves on additional share issues and announces acceptance of premature conversion of convertible debentures

The board of directors of Simris Group AB (publ) (“Simris Group” or the “Company”) has today resolved on a directed issue of units consisting of one (1) class B share and two (2) warrants of series 2025/2027 by virtue of the authorization from the annual general meeting (the “Directed Issue”). The board has further resolved to consign to an extraordinary general meeting to resolve on amendments to the articles of association and on a potential directed issue of units consisting of one (1) class B share and two (2) warrants of series 2026/2027 to certain investors (the “Investment Issue”). The board has further, based on the investors request and the board being conflicted in relation to conversion of its loan, resolved to consign to an extraordinary general meeting to resolve on a potential directed issue of class B shares to the management of the Company (the “Management Issue”). The board of directors will convene an extraordinary general meeting to be held on or around 19 January 2026. The notice for the extraordinary general meeting will be announced through a separate press release.